---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-116353"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2022-04-25T23:59:59+00:00"
generated_at: "2026-06-26T05:06:45.199598+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Nkarta reports 60% CR for NKX101 in AML; 83% ORR for NKX019 in NHL

## Summary
- NKX101: 3/5 AML patients at 1B/1.5B cells x3 achieved CR (60%); 2 of 3 CRs are MRD negative.
- NKX019: 5/6 NHL patients at 1B cells x3 achieved response (83% ORR); 3/6 CR (50% CR).
- No CRS, neurotoxicity, or GvHD reported for either program; safety profile favorable.
- Both programs advancing to 1.5B cells x3 dose regimen for recommended Phase 2 dose.
- Phase 1 trials continue enrolling; updated data to be submitted to future medical meeting.

## SEC filing metadata
- accession: 0001193125-22-116353
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2022-04-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000119312522116353/0001193125-22-116353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000119312522116353/d219241d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-116353
- JSON: https://secwatch.observer/filing/0001193125-22-116353.json
- Plain text: https://secwatch.observer/filing/0001193125-22-116353.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.